Capricor Therapeutics' shares fell about 67% after FDA reviewers raised concerns about the effectiveness evidence for its experimental Duchenne muscular dystrophy therapy, deramiocel. The FDA criticized changes in the company's trial data analysis and questioned whether the therapy reached the heart sufficiently to provide benefit. The therapy is under review with a decision expected by August 22, with no current FDA-approved treatments specifically for Duchenne-related heart issues. Capricor remains confident in its therapy despite the FDA's concerns.
Litecoin whale addresses holding $1M-$10M and above $10M have decreased to levels last seen at the 2022 market bottom, signaling reduced large-holder activity during this market phase. On-chain analyst Joao Wedson notes this contraction resembles pas...
Sui (SUI) price trades near $0.72 after a fresh TD Sequential buy signal on the 12-hour chart, which previously predicted a 17% rally and momentum shift. The price tests a critical support zone between $0.71 and $0.73, with a break below $0.71 potent...
Ripple sees a $13 trillion opportunity in the corporate treasury sector for expanding its stablecoin business, leveraging its Ripple Treasury platform acquired through GTreasury. With around 1,200 corporate clients managing cross-border and domestic ...
Bitcoin is losing its status as independent 'digital gold' and is now closely tracking the U.S. stock market, particularly the S&P 500. This growing correlation raises concerns that Bitcoin could face a sharp decline if U.S. equities correct, especia...
Saudi Arabia closed its critical East-West oil pipeline after it was damaged by drones launched from Iraq, causing crude oil prices to rise over 2%. The pipeline, which can carry 7 million barrels per day, bypasses the Strait of Hormuz and has been v...
